This edition of Diabetologia is a transitional issue, as I take over the role of Editor-in-Chief from Edwin Gale who for the past 7 years has provided visionary guidance over our journal. Diabetologia has been the society journal for the European Association for the Study of Diabetes since 1965 and under Edwin Gale's tenure interest in the journal has continued to grow, with close to 2,000 submissions per year. Even in the fast-paced electronic world of publishing and despite the establishment of many new journals in our field, Diabetologia remains one of the premier journals for original clinical and experimental research within the field of diabetes. Edwin Gale's impressive dedication to the journal, with a personal touch, will not be forgotten. Indeed, he is a hard act to follow! I extend my own personal gratitude to Edwin for his endless devotion to maintaining Diabetologia at the forefront of publishing the latest discoveries in diabetes research and care.
For those of you who are unfamiliar with me, I was born in Milwaukee (WI, USA). I earned an undergraduate degree (BS) from the University of Wisconsin-River Falls in physical education/secondary education and business administration. I admit this is an unusual combination, but I was good at sports and had planned to be a teacher. The business degree was pursued on the sound advice of my father, who thought that exposure to courses in management, finance and accounting would not hurt. Certainly, when filling out grant budgets I find he was correct! Because of my interest and involvement in competitive sports, including field hockey, athletics and swimming, I was fascinated by exercise physiology. So, rather than applying for teaching positions in high schools (or hitting Wall Street), I decided to enter Ball State University (Muncie, IN, USA) where I earned an MA in exercise science with a thesis focused on bone mineral content following swim and run training. At that time the link between athletic-induced amenorrhea and severe bone loss was becoming a concern among elite women endurance runners. This research experience sparked my interest in a career in science and I was sold. Upon graduation, I moved to Washington University School of Medicine (St Louis, MO, USA), to join the laboratory of John O. Holloszy and contributed to the ongoing research in his group on mechanisms involved in the regulation of glucose transport in skeletal muscle. This was a perfect place for me because the main focus of the research was type 2 diabetes and the health benefits of exercise. Because of the long history of Scandinavian scientists in the field of exercise physiology, I turned to Sweden when I began to consider further qualifications. In 1989 I moved to Stockholm and enrolled in the PhD programme at the Karolinska Institutet (Stockholm, Sweden). I joined the group of Harriet Wallberg-Henriksson in the Department of Clinical Physiology, led by John Wahren who was the recipient of the Minkowski Prize in 1977. There I found the perfect place to continue my interest in metabolic research. In addition, I had the opportunity to work on several projects related to the genetics of type 2 diabetes on a 6 month visit to Oluf Pedersen at the Steno Diabetes Center in Copenhagen and a post-doctoral fellowship on metabolic research at Harvard Medical School (Boston, MA, USA) with Barbara Kahn. I admit that I have had a fairly eclectic background and have ended up far from Milwaukee. I am currently Professor of Physiology and Head of the Section of Integrative Physiology of the Department of Molecular Medicine and Surgery at the Karolinska Institutet. I am fortunate to work with a dynamic group of talented young people who are conducting research on the cellular mechanisms underlying the development of insulin resistance in type 2 diabetes. I am still active in sports, and I imagine I will need all my speed and endurance in the next few years as I take on the great challenge of serving the diabetes community as Editor-in-Chief of Diabetologia.
When Edwin took the helm of Diabetologia, he recruited Judy Naylor as Managing Editor, and together they established a strong editorial office staffed with cheerful, efficient and highly competent individuals. Previously, as an Associate Editor for the journal, I had the opportunity to work closely with the Editorial Office in Bristol and I learned first hand of their valuable 'behind-the-scenes' contributions to the journal. Thus, I am delighted that Judy has agreed to continue in her role and that the EASD is able to retain the Editorial Office and staff in Bristol. Part of the success of any journal can be directly tracked to the Editorial Office and I am grateful that we have a front office with several years of experience to make this transition, as well as our future work, smooth.
One of the special aspects of Diabetologia is the emphasis on both original clinical and experimental research within the field of diabetes. Throughout my years at the Karolinska Institutet, I have appreciated the close contact between clinical and experimental researchers. Clearly, early Swedish leaders in our field, such as Rolf Luft (Karolinska Institutet; founding member and past president of the International Diabetes Federation and founding member of the EASD) and Claes Hellerström (Uppsala University; Editor of Diabetologia 1988-1993), were able to benefit from a translational approach in endocrine and metabolic research with close interactions between basic and clinical scientists. These leaders set the standard for a tight union between clinical and experimental scientists. In this regard, Diabetologia is rather unique, since both clinical and experimental studies are published under one cover.
To ensure that we continue to cover the wide spectrum of diabetes research, I have appointed John Nolan as Deputy Editor. John leads the Diabetes and Metabolism group at Trinity College (Dublin, Ireland) and is consultant endocrinologist at St James's Hospital (Dublin, Ireland). He is a Fellow of the Royal Colleges of Physicians in Ireland and Edinburgh. He has been actively engaged with the EASD and has most recently served as Associate Editor for Diabetologia and Chair of Postgraduate Education for the EASD. Together, John and I will rely on the talented team of Associate Editors who collectively represent the European and international diabetes community. Our Associate Editors themselves are ahead of the scientific curve. Each of these associates handles up to 100 manuscripts per year, so the workload is demanding, and we rely on our Associate Editors to maintain the highest level of scientific excellence. This can be appreciated by the fact that the journal now has an average acceptance rate of 20% and an impact factor of 6.551-the highest ever for the journal. Looking at this from the other side of the equation, about 80% of the manuscripts submitted to Diabetologia receive the dreaded letter of rejection. Many papers are rejected based on the descriptive nature or the seemingly incremental advance of the study. Other papers that are sure to be doomed are those that contain the smallest publishable unit rather than the complete documentation of the study. We do have a rapid triage system that allows authors to redirect their paper to a more appropriate journal without delay. The competition to publish good papers is fierce and the journal will continue to publish reports of clinical and experimental work on all aspects of diabetes research and related subjects, provided they have scientific merit and represent an important mechanistic or clinical advance in knowledge. Diabetologia represents the global scientific community. Yes, we are the society journal of the EASD, but that in no way means our outreach is limited to European countries. Diabetologia has a global presence and received manuscripts from 54 countries from the start of the year up to 20 September 2010 (Fig. 1) . Globalisation has been our business for decades and will continue to be so going forward! Although there are regional differences in genetics, pathogenesis and care, diabetes is a disease that touches all corners of the world. Therefore, international collaborations are required to better understand the mechanisms causing diabetes, as well as effective treatment strategies to manage this disease. While it is not our policy to solicit manuscripts from specific parts of the world, we encourage online submissions from all regions of the global diabetes community. One benefit associated with membership of the EASD is the fact that each month a personal copy of Diabetologia is delivered to your desk. This provides thousands of individuals with direct access to the latest developments from the front line of experimental and clinical research. If you are not a member of the EASD, you can still have access to Diabetologia by contacting our publisher.
To keep up with the fast pace of publishing, our Associate Editors are committed to securing rapid and thorough reviews of relevant papers from expert international reviewers. Decisions are currently delivered to authors within 3 weeks of submission and accepted papers are now published online for immediate access within 5 weeks of the final decision. Online access to your paper will be free for the first 30 days after it has been uploaded onto the publisher's website. Online access to all papers is free 12 months after print publication. Diabetologia has a worldwide print circulation of 7,000, putting the journal in the hands of thousands of individuals committed to diabetes research and care.
Thus, in closing, I wish to extend my deepest gratitude to Edwin Gale for his extraordinary work with Diabetologia. Together with the Editorial Staff, we will endeavour to keep the journal moving along the sound course you have set. Recognising the fact that science, as well as publishing, is an evolving process, we will continue to develop Diabetologia to reflect the changing needs of our community. Reflecting upon the title of this Editorial, one must remember that even as we move along at an ever-increasing pace in our scientific pursuits, it is quality rather than quantity that matters.
I close with a quote below from Alfred Nobel (1833-1896), the Swedish chemist, engineer and inventor, who used his great fortune to establish the Nobel Prizes:
'If I have a thousand ideas and only one turns out to be good, I am satisfied.'
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